Literature DB >> 19115474

Seroepidemiology of hepatitis A virus in Kuwait.

Jameela Alkhalidi1, Bader Alenezi, Seham Al-Mufti, Entisar Hussain, Haifa Askar, Nyingi Kemmer, Guy W Neff.   

Abstract

AIM: To find the current seroepidemiology of hepatitis A virus (HAV) in Kuwait.
METHODS: A total of 2851 Kuwaitis applying for new jobs were screened.
RESULTS: HAV-positive cases were 28.8%; 59% were males and 41% were females. The highest prevalence was in the Ahmadi area. High prevalence was among the group of non-educated rather than educated parents. This is the first study in Kuwait demonstrating the shifting epidemiology of HAV.
CONCLUSION: This study reflects the need of the Kuwaiti population for an HAV vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19115474      PMCID: PMC2653286          DOI: 10.3748/wjg.15.102

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

Review 1.  Type A viral hepatitis. New developments in an old disease.

Authors:  S M Lemon
Journal:  N Engl J Med       Date:  1985-10-24       Impact factor: 91.245

2.  Hepatitis A infection: a seroepidemiological study in young adults in North-East Italy.

Authors:  M E Moschen; A Floreani; E Zamparo; V Baldo; S Majori; V Gasparini; R Trivello
Journal:  Eur J Epidemiol       Date:  1997-12       Impact factor: 8.082

3.  Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1996-07-12

4.  Hepatitis A virus infection in a chimpanzee: duration of viremia and detection of virus in saliva and throat swabs.

Authors:  J I Cohen; S Feinstone; R H Purcell
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

5.  Inactivated hepatitis A vaccine: long-term antibody persistence.

Authors:  G Wiedermann; M Kundi; F Ambrosch; A Safary; E D'Hondt; A Delem
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

6.  Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA.

Authors:  Alan Werzberger; Barbara Mensch; David R Nalin; Barbara J Kuter
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

7.  Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C.

Authors:  S Vento; T Garofano; C Renzini; F Cainelli; F Casali; G Ghironzi; T Ferraro; E Concia
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

8.  Quantification and duration of viraemia during hepatitis A infection as determined by real-time RT-PCR.

Authors:  M Costa-Mattioli; S Monpoeho; E Nicand; M-H Aleman; S Billaudel; V Ferré
Journal:  J Viral Hepat       Date:  2002-03       Impact factor: 3.728

9.  Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness.

Authors:  S M Feinstone; A Z Kapikian; R H Purceli
Journal:  Science       Date:  1973-12-07       Impact factor: 47.728

10.  A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children.

Authors:  A Werzberger; B Mensch; B Kuter; L Brown; J Lewis; R Sitrin; W Miller; D Shouval; B Wiens; G Calandra
Journal:  N Engl J Med       Date:  1992-08-13       Impact factor: 91.245

View more
  5 in total

1.  Hepatitis A: Epidemiology and prevention in developing countries.

Authors:  Elisabetta Franco; Cristina Meleleo; Laura Serino; Debora Sorbara; Laura Zaratti
Journal:  World J Hepatol       Date:  2012-03-27

Review 2.  Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran.

Authors:  Ziba Farajzadegan; Shervin Ghaffari Hoseini; Roya Kelishadi; Fahimeh Jamshidi; Zari Nokhodian; Rasool Noori; Parisa Mirmoghtadaee; Silva Hovsepian; Seyyed-Nassereddin Mostafavi
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

3.  Comparison of the Prevalence and Risk Factors of Hepatitis A in 10 to 18-Year-Old Adolescents of Sixteen Iranian Provinces: The CASPIAN-III Study.

Authors:  Nasser Mostafavi; Roya Kelishadi; Elham Kazemi; Behrooz Ataei; Majid Yaran; Mohammad Esmaeil Motlagh; Mostafa Qorbani; Ramin Heshmat; Mohamad Hasan Tajadini; Shervin Ghaffari Hoseini
Journal:  Hepat Mon       Date:  2016-08-17       Impact factor: 0.660

4.  Evidence of Circulation of Several HAV Genetic Variants and Emergence of Potential Antigenic Variants in an Endemo-Epidemic Country before Vaccine Introduction.

Authors:  Kaouther Ayouni; Anissa Chouikha; Oussema Khamessi; Henda Touzi; Walid Hammemi; Henda Triki
Journal:  Viruses       Date:  2021-06-03       Impact factor: 5.048

5.  Seroprevalence of anti-hepatitis a antibody among 1 - 15 year old children in kashan-iran.

Authors:  Abbas Taghavi Ardakani; Babak Soltani; Mojtaba Sehat; Somayeh Namjoo; Mostafa Haji Rezaei
Journal:  Hepat Mon       Date:  2013-05-27       Impact factor: 0.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.